Receives Approval Notice for New Clinical Trial of Innovative Drug HSK39297 Tablets
November 15, 2025
Source: drugdu
92
Haisco On November 13, the company announced that its HSK39297 tablets had received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, approving the company to conduct clinical trials. The indication is age-related macular degeneration.
https://finance.eastmoney.com/a/202511133563521296.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
